Search Cancer Clinical Trials

Mass General Brigham Cancer Institute offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Search by condition
Search By:
28 results
  • Ovarian Cancer, Head and Neck Cancer, Breast Cancer, Cervical Cancer

21-689          Phase I

A First-in-Human Study of Mutant-selective PI3Ka Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer

  • Pancreatic Cancer, Lung Cancer, Ovarian Cancer, Liver Cancer, Kidney Cancer, Head and Neck Cancer, Breast Cancer, Thyroid Cancer, Sarcoma

23-301          Phase I

A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants with Advanced Solid Tumors

  • Sarcoma, Gastric (Stomach) Cancer, Ovarian Cancer

24-169          Phase I

A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination with the ATR Inhibitor M1774

  • Prostate Cancer, Ovarian Cancer, Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Cervical Cancer, Breast Cancer, Bladder Cancer, Pancreatic Cancer

24-114          Phase I

A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastatic Solid Tumors

  • Ovarian Cancer

24-472          Phase I

A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (anti-FRa antibody-drug conjugate) in Adult Patients with Recurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

  • Endometrial Cancer, Breast Cancer, Ovarian Cancer, Cervical Cancer

25-490          Phase I

A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination with other Anticancer Agents in Participants with Advanced Solid Tumors

  • Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Melanoma, Lung Cancer, Head and Neck Cancer, Gastric (Stomach) Cancer, Esophageal Cancer, Colorectal Cancer, Cervical Cancer, Bladder Cancer, Breast Cancer

25-287          Phase I

A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a Single Agent in Advanced Solid Tumors

  • Uterine Cancer, Ovarian Cancer, Melanoma, Lung Cancer, Endometrial Cancer, Bladder Cancer, Breast Cancer

22-430          Phase II

A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers

  • Ovarian Cancer, Lung Cancer, Head and Neck Cancer, Endometrial Cancer, Esophageal Cancer

25-622          Phase II

A Phase 1/2 Trial of TER-2013 in Participants with Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

  • Ovarian Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, Prostate Cancer

22-577          Phase II

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that are Antigen-rich (START-001)

Showing 1 - 10 of 28 results